GSK Augmentin 875 mg/125 mg

Augmentin is a widely recognized broad-spectrum antibiotic consisting of amoxicillin and clavulanic acid. It was originally developed and patented in 1977 by the British company Beecham Group (which later became part of SmithKline Beecham). The brand is a cornerstone of the penicillin-based antibiotic market, designed to overcome bacterial resistance.

Manufacturing of Augmentin occurs across several specialized facilities globally. Significant production sites include GSK's antibiotic plants in Irvine and Worthing in the United Kingdom, as well as facilities in Mayenne, France. These sites produce both the active pharmaceutical ingredients (API) and the finished solid dose tablets for global distribution.

Ownership of the brand transitioned through several major corporate mergers. Beecham Group merged with SmithKline Beckman in 1989 to form SmithKline Beecham, which then merged with Glaxo Wellcome in 2000 to create GlaxoSmithKline (GSK). Today, the brand remains under the ultimate ownership of GSK plc, a British multinational biopharma leader headquartered in London.